V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 230000419 | 230000244 | 1.7 | null | Palliative (P) | null | 2014-03-19 | Sorafenib | null | N | 230003308 | CAPECITABINE + OXALIPLATIN |
| 230000420 | 230000245 | 1.52 | 56.8 | null | 2016-08-09 | 2016-08-24 | PLATO Trials | N | null | 230003313 | IRINOTECAN + MDG |
| 230000421 | 230000245 | null | 74.4 | Palliative (P) | 2017-05-10 | 2017-05-29 | Oxaliplatin + Modified de Gramont | N | null | 230003313 | CAPECITABINE |
| 230000422 | 230000246 | 1.75 | 97.1 | Adjuvant (A) | 2016-08-31 | 2016-09-26 | CAPECITABINE + OXALIPLATIN | N | N | 230003331 | CAPECITABINE + OXALIPLATIN |
| 230000423 | 230000247 | 1.6 | 70.8 | Palliative (P) | 2015-10-15 | 2015-10-15 | Sorafenib | N | N | 230003338 | OXALIPLATIN + MDG |
| 230000424 | 230000248 | 1.74 | 92.3 | Palliative (P) | 2013-10-14 | 2013-11-05 | IRINOTECAN + MDG | 2 | N | 230003340 | IRINOTECAN + MDG |
| 230000425 | 230000249 | 1.55 | 83.9 | Neo-adjuvant (N) | 2016-07-12 | 2016-07-17 | Sorafenib | 02 | N | 230003366 | OXALIPLATIN + MDG |
| 230000426 | 230000249 | 1.7 | null | Palliative (P) | 2015-01-21 | 2015-01-28 | Oxaliplatin + Modified de Gramont | null | N | 230003366 | IRINOTECAN + MDG |
| 230000427 | 230001487 | 1.51 | 64.7 | Adjuvant (A) | 2014-01-14 | 2014-01-23 | Sorafenib | 2 | N | 230003415 | CAPECITABINE + OXALIPLATIN |
| 230000428 | 230000250 | 1.63 | 101.8 | Adjuvant (A) | 2014-02-15 | 2014-04-04 | VANDETANIB | N | N | 230003426 | BEVACIZUMAB + CAPE + IRINOTECAN |
| 230000429 | 230000250 | 1.71 | null | Adjuvant (A) | 2008-07-18 | 2013-04-21 | Capecitabine | 02 | N | 230003426 | CAPECITABINE |
| 230000430 | 230000251 | 1.75 | 79.4 | Adjuvant (A) | 2013-08-17 | 2013-09-01 | Cetuximab + FOLFIRI cycle1 | 2 | Y | 230003475 | IRINOTECAN + MDG |
| 230000431 | 230000252 | 1.64 | 65.3 | Adjuvant (A) | 2013-08-31 | 2013-08-31 | VANDETANIB | N | null | 230003506 | CARBOPLATIN + PEMETREXED |
| 230000432 | 230001145 | 1.62 | 82 | Palliative (P) | null | 2017-06-05 | Bevacizumab + Cape + Oxali 21day | 2 | N | 230003507 | CAPECITABINE + OXALIPLATIN |
| 230000433 | 230000253 | null | 84.5 | Adjuvant (A) | 2018-04-26 | 2018-05-02 | Sorafenib | N | N | 230003511 | OXALIPLATIN + MDG |
| 230000434 | 230000254 | -1 | 71.6 | Palliative (P) | 2015-07-15 | 2015-08-01 | Carboplatin + Etoposide IV 3 day | N | null | 230003531 | CAPECITABINE + OXALIPLATIN |
| 230000435 | 230000255 | null | 42.2 | Palliative (P) | 2014-10-26 | 2014-11-02 | Oxaliplatin + Modified de Gramont | N | N | 230003539 | CAPECITABINE + RT |
| 230000436 | 230000256 | 1.66 | 67 | null | 2017-10-31 | 2017-11-06 | Oxaliplatin + Modified de Gramont | N | N | 230003590 | CAPECITABINE + RT |
| 230000437 | 230000256 | null | 51.4 | Palliative (P) | 2014-01-16 | 2014-01-25 | Fluorouracil + Folinic Acid Weekly | N | N | 230003590 | CAPECITABINE |
| 230000438 | 230000256 | 1.77 | 95.2 | Palliative (P) | null | 2017-11-25 | Irinotecan + Modified De Gramont | N | N | 230003590 | FLUOROURACIL |
| 230000439 | 230000256 | 1.6 | 61.3 | Disease modification (D) | 2017-11-30 | 2017-12-05 | Azacitidine | 02 | Y | 230003590 | CAPECITABINE |
| 230000440 | 230000257 | null | null | null | 2016-10-09 | 2016-11-12 | CARBOPLATIN + PACLITAXEL | N | null | 230003642 | CAPECITABINE + OXALIPLATIN |
| 230000441 | 230000257 | 1.73 | 76.7 | Curative (C) | 2015-05-29 | 2015-08-13 | Cape + Cetuximab +Irinotecan - Load | N | N | 230003642 | CAPECITABINE + IRINOTECAN |
| 230000442 | 230000257 | null | 78.9 | Adjuvant (A) | 2017-07-02 | 2017-07-15 | CAPECITABINE + MITOMYCIN + RT | 02 | N | 230003642 | OXALIPLATIN + MDG |
| 230000443 | 230000257 | 1.78 | 77.5 | Palliative (P) | 2017-02-12 | 2017-03-01 | Liposomal Doxorubicin (Caelyx) | N | N | 230003642 | CAPECITABINE |
| 230000444 | 230000258 | 1.82 | 77.9 | Adjuvant (A) | null | 2015-12-01 | Cisplatin + Doxorubicin | N | N | 230003741 | CAPECITABINE |
| 230000445 | 230000259 | 1.78 | 105 | Not known (9) | null | 2013-06-16 | Capecitabine + Oxaliplatin 21day | N | N | 230003748 | CAPECITABINE + MITOMYCIN |
| 230000446 | 230000260 | null | 33 | null | 2016-03-20 | 2016-03-27 | VANDETANIB | N | null | 230003759 | CAPECITABINE + MITOMYCIN + RT |
| 230000447 | 230000261 | 1.61 | 68.5 | Adjuvant (A) | 2018-07-14 | 2018-07-27 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | 230003771 | BEVACIZUMAB + OXALIPLATIN + MdG |
| 230000448 | 230000262 | 1.73 | 106.2 | Palliative (P) | 2017-01-02 | 2017-01-14 | Sorafenib | N | null | 230003812 | FLUOROURACIL |
| 230000449 | 230000263 | 1.58 | 57 | Neo-adjuvant (N) | 2018-09-15 | 2018-09-21 | VANDETANIB | 02 | N | 230003846 | CAPECITABINE |
| 230000450 | 230000264 | 1.63 | 71.3 | Adjuvant (A) | 2015-12-20 | 2015-12-23 | Sorafenib | N | N | 230003885 | OXALIPLATIN + MDG |
| 230000451 | 230000265 | 1.73 | 95.2 | Palliative (P) | 2017-12-02 | 2017-12-02 | Sorafenib | N | null | 230003903 | SORAFENIB |
| 230000452 | 230000265 | 1.78 | 60 | Adjuvant (A) | 2017-06-12 | 2017-06-12 | Oxaliplatin + Modified de Gramont | 02 | N | 230003903 | OXALIPLATIN + MDG |
| 230000453 | 230000266 | 1.79 | 146 | Adjuvant (A) | null | 2013-10-24 | Gemcitabine 1000mg/m2 D1 8 15 | N | N | 230003939 | OXALIPLATIN + MDG |
| 230000454 | 230000267 | 1.6 | 56.5 | Curative (C) | 2016-09-23 | 2016-10-16 | Oxaliplatin + Modified de Gramont | N | N | 230003940 | CAPECITABINE + RT |
| 230000455 | 230000267 | 1.68 | 78.9 | Palliative (P) | 2014-07-27 | 2014-08-02 | IVA | N | N | 230003940 | CAPECITABINE + OXALIPLATIN |
| 230000456 | 230000268 | 1.66 | null | Curative (C) | 2013-07-16 | 2013-07-16 | Trastuzumab Subcutaneous | N | Y | 230003958 | IRINOTECAN + MDG |
| 230000457 | 230000269 | 1.83 | 85.2 | Adjuvant (A) | 2017-07-27 | 2017-07-29 | Cisplatin + Pemetrexed | N | N | 230003993 | CAPECITABINE + OXALIPLATIN |
| 230000458 | 230000270 | -1 | 56.7 | Palliative (P) | 2016-10-03 | 2016-10-09 | Capecitabine + Mitomycin | N | N | 230004007 | TEMOZOLOMIDE |
| 230000459 | 230000271 | 1.77 | 106.2 | Adjuvant (A) | 2014-10-03 | 2014-10-07 | PEMBROLIZUMAB | 02 | N | 230004016 | CAPECITABINE + OXALIPLATIN |
| 230000460 | 230000271 | 1.63 | 111 | Curative (C) | 2009-10-29 | 2016-02-12 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | 230004016 | IRINOTECAN + MDG |
| 230000461 | 230000271 | 1.65 | 51.4 | Disease modification (D) | 2016-04-18 | 2016-05-09 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | 230004016 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 230000462 | 230000271 | 1.88 | 68.3 | Palliative (P) | 2015-02-16 | 2015-03-06 | Bendamustine+Rituximab (1st Course) | 02 | N | 230004016 | CAPECITABINE |
| 230000463 | 230000271 | 1.62 | 78.8 | Palliative (P) | 2018-04-26 | 2018-05-11 | CHOP R - 21 days | N | N | 230004016 | OXALIPLATIN + MDG |
| 230000464 | 230000271 | 1.87 | 96.1 | Palliative (P) | 2013-08-22 | 2013-09-12 | Capecitabine | N | N | 230004016 | CAPECITABINE + RT |
| 230000465 | 230000272 | 1.86 | 87 | Disease modification (D) | 2014-11-04 | 2014-11-11 | Cabazitaxel | 2 | N | 230004071 | CAPECITABINE + OXALIPLATIN |
| 230000466 | 230000272 | 1.62 | 65 | Palliative (P) | 2016-06-04 | 2016-06-24 | Bevacizumab + Cape + Oxali 21day | 02 | N | 230004071 | CAPECITABINE |
| 230000467 | 230001491 | 1.48 | 53.1 | Curative (C) | 2013-04-07 | 2013-09-22 | CARBOPLATIN | 2 | N | 230004088 | CVP R |
| 230000468 | 230000273 | 1.77 | 90 | Adjuvant (A) | 2014-01-08 | 2014-01-08 | VANDETANIB | N | null | 230004093 | VANDETANIB |